Astra M. Liepa - Concepedia

Author

Astra M. Liepa

Also Known As

A M Liepa, A. Liepa, A. M. Liepa, A.M Liepa, A.M. Liepa, Agris Liepa, Astra Liepa, Astra M Liepa, Astra M. Liepa, Liepa, Astra M.

128

Publications

5.3K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)National Cancer Center Hospital East Royal Marsden Hospital University of Turin University of California, Los Angeles

About

Astra M. Liepa is an author at Eli Lilly (United States) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	26	3.8K
2	Health Sciences	10	11	368
3	Public Health	1	1	549
4	Clinical Immunology	1	1	98
5	Family Medicine	1	1	549

Astra M. Liepa

Publications

5.1K

Citations

H-Index

Page 1

	Year	Citations
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial Charles S. Fuchs, Jiří Tomášek, Filip Dumitru, The Lancet Surgical OncologyEsophageal CancerGastrointestinal OncologyGastro-oesophageal Junction AdenocarcinomaMedicine	2013	2.2K
What Is Sufficient Evidence for the Reliability and Validity of Patient-Reported Outcome Measures? Marlene H. Frost, Bryce B. Reeve, Astra M. Liepa, Value in Health ReliabilityFamily MedicineHealth PolicyClinical EffectivenessHealth Care Reimbursement	2007	549
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma Wolfgang Wick, Vinay K. Puduvalli, Marc C. Chamberlain, Journal of Clinical Oncology	2010	507
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial Daniel P. Petrylak, Ronald de Wit, Kim N., The Lancet Platinum-based TherapyUrologyMetastatic Urothelial CarcinomaGenitourinary CancerMedicine	2017	175
Health-Related Quality-of-Life Parameters as Independent Prognostic Factors in Advanced or Metastatic Bladder Cancer D. Roychowdhury, A. Hayden, Astra M. Liepa Journal of Clinical Oncology	2003	119
Quality-of-Life Improvements in Cutaneous T-Cell Lymphoma Patients Treated with Denileukin Diftitox (ONTAK®) Madeleine Duvic, Timothy M. Kuzel, Elise A. Olsen, Clinical Lymphoma Clinical ImmunologyLymphoid NeoplasiaQuality-of-life ImprovementsMedicineImmunodeficiencies	2002	98
Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer Kohei Shitara, Kei Muro, Yasuhiro Shimada, Gastric Cancer Gastrointestinal OncologyMedicineGastroenterologyClinical TrialsPathology	2015	83
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial Daniel P. Petrylak, Ronald de Wit, Kim N., The Lancet Oncology Platinum-based TherapyUrologyGenitourinary CancerMedicineDocetaxel Versus Placebo	2019	83
Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma Salah‐Eddin Al‐Batran, Eric Van Cutsem, Sang Cheul Oh, Annals of Oncology	2016	76
Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data Charles S. Fuchs, Kei Muro, Jiří Tomášek, Journal of the Korean Gastric Cancer Association	2017	71

Page 1